Artemis Medicare Services Limited has notified the stock exchanges of a change in its board composition, disclosing that Mr. Sunil Tandon has ceased to be a Director of the company. The development was communicated pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and was filed by Company Secretary and Compliance Officer Poonam Makkar on May 10, 2026.

Board Change: Cessation of Independent Director

Mr. Sunil Tandon (DIN: 08342585) stepped down from the board of Artemis Medicare Services upon the completion of his tenure as an Independent Director on May 9, 2026. The cessation was a result of the natural expiry of his term and does not indicate any other circumstance. The company has disclosed the required details in accordance with Schedule III of the SEBI Listing Regulations.

Key Details of the Change

The following information has been provided by the company as required under Regulation 30 and Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Regulatory Compliance

The intimation was submitted to both the National Stock Exchange of India Limited and BSE Limited in compliance with applicable listing regulations. The filing was signed and submitted by Poonam Makkar, Company Secretary and Compliance Officer of Artemis Medicare Services, on May 10, 2026. No further details regarding a replacement appointment were disclosed as part of this filing.

Artemis Medicare Services held its Board of Directors meeting on May 8, 2026, approving the audited financial results for the quarter and year ended March 31, 2026, on both standalone and consolidated bases. The board recommended a final dividend of Re. 0.45 per equity share of face value Re. 1 each (i.e., 45%) for FY26, subject to shareholder approval at the ensuing Annual General Meeting. Additionally, the board appointed Mr. Tapan Mitra as an Additional Director in the capacity of Independent Director for a period of 3 years, effective from May 8, 2026, subject to AGM approval. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audited financial results for the quarter and year ended March 31, 2026 were subsequently published in The Financial Express (English National Daily Newspaper – all editions) and The Jansatta (Hindi National Daily Newspaper – Delhi edition) on May 9, 2026.

Standalone Financial Performance

On a standalone basis, the company reported revenue from operations of ₹27,378.66 lacs for Q4 FY26, compared to ₹23,480.13 lacs in the previous year. Net profit after tax for the quarter stood at ₹2,954.70 lacs against ₹2,320.46 lacs in Q4 FY25. For the full year FY26, standalone revenue from operations reached ₹1,06,049.17 lacs, up from ₹91,326.13 lacs in FY25, while net profit after tax increased to ₹10,344.15 lacs from ₹8,345.78 lacs. The company recognized an exceptional item of ₹307.44 lacs during the year, representing the incremental impact on gratuity and leave liability arising from the Labour Codes notified by the Government of India.

* Not annualised

Consolidated Financial Performance

On a consolidated basis, encompassing Artemis Medicare Services Limited and its subsidiary Artemis Cardiac Care Private Limited, the group reported revenue from operations of ₹27,922.64 lacs for Q4 FY26, up 16.4% from ₹23,990.01 lacs in Q4 FY25. Consolidated net profit after tax for the quarter stood at ₹3,028.10 lacs, a growth of 32.1% against ₹2,292.39 lacs in the previous year. For the full year FY26, consolidated revenue from operations rose 15.4% to ₹1,08,124.24 lacs from ₹93,691.67 lacs in FY25. Consolidated net profit after tax for the year stood at ₹10,371.52 lacs, a growth of 26.2% against ₹8,217.62 lacs in the previous year, while consolidated EBITDA grew 18.0% to ₹21,801 lacs from ₹18,478 lacs.

* Not annualised

Artemis Hospital Gurgaon Operational Highlights

The flagship Artemis Hospital Gurgaon facility was a key driver of performance during the period. For Q4 FY26, revenue from operations stood at ₹26,746 lacs, an increase of 18.8% from ₹22,520 lacs in Q4 FY25. EBITDA for the quarter grew 20.6% to ₹5,804 lacs, while PAT increased 19.8% to ₹3,136 lacs. The hospital reported an Average Revenue Per Occupied Bed (ARPOB) of ₹84,571 and bed capacity utilization of 64.6%. For the full year FY26, the facility recorded revenue of ₹1,03,022 lacs, up 17.8% from ₹87,424 lacs in FY25, with an EBITDA of ₹21,785 lacs and PAT of ₹11,336 lacs.

Corporate Actions and Governance

The board approved the re-appointment of M/s. T R Chadha & Co LLP as Statutory Auditors for a second term of 5 years, from the conclusion of the 22nd AGM to the 27th AGM (year 2031), subject to AGM approval. Additionally, the board approved the extension of the period for utilization of unutilized funds from the proceeds of the preferential issue by 18 months, without any change in the objects of the issue. The company also entered into a Medical Services Agreement with Dr. Vidya Sagar Kaushalya Devi Memorial Health Centre (VIMHANS), paying an advance of ₹6,962 lacs during the quarter ended March 31, 2026, aggregating to ₹12,862 lacs as at that date, and providing a bank guarantee of ₹5,900 lacs.